Skin Cancer Diagnostics Market To Reach $15.67 Billion By 2033

Skin Cancer Diagnostics Market Growth & Trends

The global skin cancer diagnostics market size is anticipated to reach USD 15.67 billion by 2033 and is expected to expand at a CAGR of 5.7% from 2025 to 2033, according to a new report by Grand View Research, Inc. The skin cancer diagnostics market is driven by several key factors. Rising skin cancer incidence due to increased UV exposure and aging populations is a primary driver. Advances in diagnostic technologies, such as AI-powered imaging and molecular diagnostics, enhance accuracy and early detection, further propelling market growth. Increased awareness campaigns and government initiatives promoting early screening also contribute significantly. In addition, higher healthcare expenditures and improved access to dermatological care are crucial in expanding the skin cancer diagnostics market.

Over the past decade, significant advancements have been made in approaches to melanoma detection, all aimed at reducing the growing incidence of melanoma and its mortality rate. While these advancements have been well-documented to increase early melanoma detection, there has been considerable criticism of their efficacy in improving survival rates. Traditional methods for detecting skin cancer often involve time-consuming and expensive procedures, such as PET and CT scans, as well as invasive technologies using higher frequencies.

A biosensor developed at Queen Mary University of London in April 2024 offers a noninvasive and highly efficient solution. This biosensor leverages the unique properties of THz waves, which have lower energy than X-rays and are safe for humans, to detect subtle changes in cell characteristics. In addition, scientists have developed genomic tests that provide oncologists and dermatologists with valuable information about the molecular biology of tumors, particularly in patients with aggressive skin cancers such as invasive melanomas and high-risk Squamous Cell Carcinomas (SCCs). These tests analyze genetic information from a patient's primary tumor, helping physicians better forecast the likelihood of cancer recurrence after treatment and its potential spread to other parts of the body. Furthermore, these tests offer greater patient-specific insights that are not available through traditional cancer staging, which typically uses clinical information and lab reports compared with population-based data to determine a patient's prognosis.

In the era of COVID-19, teledermatology has become increasingly popular. These emerging techniques for skin cancer diagnosis have the potential to be integrated into teledermatology in primary care settings. Furthermore, combining AI with these emerging techniques can further enhance their widespread use. More large-scale, multicenter, prospective clinical trials are needed to prevent these emerging techniques from remaining experimental equipment used in only a few special centers. This can be achieved by maintaining interest in this issue among health providers, the general population, patients, and health-related organizations in each country.

 Request a free sample copy or view report summary: Skin Cancer Diagnostics Market Report

Skin Cancer Diagnostics Market Report Highlights

• The nonmelanoma segment held the largest market share of 74.8% in 2024. The rising incidence of NMSC represents a significant market driver for novel technologies in screening and diagnosis.

• The skin biopsy segment led the skin cancer diagnostics industry with a revenue share of 31.47% in 2024. Skin biopsy is a fundamental diagnostic procedure in dermatology, with various methods available for different situations.

• Hospitals and clinics led the skin cancer diagnostics market with a share of 53.39% in 2024. In addition, it is expected to be the fastest-growing segment over the forecast period.

• The North America skin cancer diagnostics market accounted for a 38.39% revenue share in 2024. Skin cancer is the most prevalent form of cancer in the U.S.; approximately one in five U.S. individuals is expected to suffer from skin cancer in their lifetime.

Skin Cancer Diagnostics Market Segmentation

Grand View Research has segmented the global skin cancer diagnostics market report based on cancer type, test type, end use, and region:

Skin Cancer Diagnostics Cancer Type Outlook (Revenue, USD Million; 2021 - 2033)

• Melanoma

• Non-Melanoma

Skin Cancer Diagnostics Test Type Outlook (Revenue, USD Million; 2021 - 2033)

• Dermatoscopy

• Skin Biopsy

• Lymph node biopsy

• Imaging Tests

• Others

Skin Cancer Diagnostics End Use Outlook (Revenue, USD Million; 2021 - 2033)

• Hospital and Clinics

• Laboratories

• Others

Skin Cancer Diagnostics Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • Kuwait

  • UAE

List of Key Players in Skin Cancer Diagnostics Market

• Castle  Bioscience

• DermTech

• bioMérieux Inc.

• FOUNDATION MEDICINE, INC.

• DermaSensor, Inc.

• F  Hoffmann-La Roche Ltd

• NeoGenomics  Laboratories

• Quest Diagnostics Incorporated.

• SkylineDx

• Abbott